EU Approvals: J&J's Darzalex Steps Ahead With New Indication
Keytruda Cleared For First-Line Head & Neck Cancer
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.
You may also be interested in...
After selling off its oncology franchise just five years ago, GSK is poised to re-enter the fray - and is preparing its commercial teams for battle.
As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.